Skip to content

PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty

RecruitingPhase 4NCT07180979
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

The goal of this clinical trial is to evaluate whether different types of regional anesthesia can improve pain control and functional recovery after total hip arthroplasty in adult patients undergoing elective hip replacement surgery. The main questions it aims to answer are: Does the PENG block reduce opioid use in the first 48 hours after surgery more effectively than the combined L-ESPB + S-ESPB technique? Which method provides better pain relief, preserves muscle strength, and supports earlier mobilization? Researchers will compare the Pericapsular Nerve Group (PENG) block with the combination of Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB + S-ESPB) to see which provides better pain control, fewer side effects, and faster recovery. Participants will: Be randomly assigned to receive one of the two types of ultrasound-guided regional anesthesia Undergo standard hip replacement surgery under spinal anesthesia Be monitored for pain scores, opioid use, time to first walking, muscle strength, satisfaction, and side effects over the first 48 hours after surgery.

Study details

Official title
Comparison of Pericapsular Nerve Group (PENG) Block Versus Lumbar Erector Spinae Plane Block (L-ESPB) Combined With Sacral ESPB (S-ESPB) for Analgesia in Total Hip Arthroplasty (THA): A Randomized Clinical Trial
Conditions
Sponsor
Poznan University of Medical Sciences
Start date
2025-09-15
Primary completion
2026-09-30
Sex
All
Age range
from 65 Years to 100 Years
Results posted
No results posted in this snapshot
Countries
Poland
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age ≥ 65 years * ASA physical status I-III * Elective unilateral THA via posterior or lateral approach * Informed consent provided Exclusion Criteria: * Allergy to study drugs (ropivacaine, dexamethasone) * Chronic opioid use (\>30 MME/day) * Coagulopathy or infection at the injection site * BMI \> 40 kg/m² * Pre-existing motor weakness or neuropathy in the affected limb * Cognitive impairment precluding informed consent

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07180979